|Sub-sector||Technology & Healthcare|
The company is dual-listed in London and New York, with a proven track record of bringing innovative oncology drugs from discovery to full commercialisation.
In 2021, Hutchmed sought primary listing status on the Hong Kong Stock Exchange (HKEX) and additional investment to support further research and development.
Macquarie secured investor interest from reputable Australian long-only funds and achieved significant demand in the bookbuild process.
The funds raised will be used to advance Hutchmed’s late-stage clinical programs and fund the continued expansion and development of cancer and immunological treatments for patients.
performance among all secondary listed companies on HKEx to date.
on HKEx with cornerstone investments.
(13 HK) once belonged to Hutchison Whampoa Ltd, one of the largest companies previously listed on HKEx.